, Volume 73, Issue 16, pp 1841–1846

Olodaterol: First Global Approval

R&D Insight Report

DOI: 10.1007/s40265-013-0137-9

Cite this article as:
Gibb, A. & Yang, L.P.H. Drugs (2013) 73: 1841. doi:10.1007/s40265-013-0137-9


Olodaterol (Striverdi® Respimat®) is a novel, long-acting, β2-adrenergic receptor agonist developed by Boehringer Ingelheim for the treatment of chronic obstructive pulmonary disease (COPD). The drug is delivered via the Respimat® Soft Mist™ inhaler. Olodaterol received its first global approval for the once-daily maintenance treatment of COPD in Canada and Russia, and submissions for regulatory approval have also been made in the USA, the EU and elsewhere. Phase II trials have been conducted in patients with asthma. The company is also developing a fixed-dose combination of olodaterol with tiotropium bromide, a long-acting anti-muscarinic agent, for the treatment of COPD. This article summarizes the milestones in the development of olodaterol leading to this first approval for COPD.

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.Adis R&D InsightNorth ShoreNew Zealand
  2. 2.AdisAucklandNew Zealand